Anika Therapeutics (ANIK) Short-term Investments (2014 - 2026)

Anika Therapeutics (ANIK) has reported Short-term Investments for 13 consecutive years, with $25.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Short-term Investments rose 17.2% year-over-year to $25.8 million in Q1 2026; TTM through Mar 2026 was $25.8 million, a 17.2% increase from a year earlier, with the FY2025 full-year figure at $23.7 million, changed 0.41% from the prior year.
• Short-term Investments was $25.8 million for Q1 2026 at Anika Therapeutics, up from $23.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $36.7 million in Q2 2023 and troughed at $22.0 million in Q1 2025.
• A 5-year average of $29.1 million and a median of $29.3 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments slumped 31.46% in 2025 and advanced 17.2% in 2026, its largest moves.
• Over 5 years, Short-term Investments stood at $34.6 million in 2022, then fell by 23.87% to $26.4 million in 2023, then declined by 10.49% to $23.6 million in 2024, then gained by 0.41% to $23.7 million in 2025, then advanced by 8.77% to $25.8 million in 2026.
• The last three Short-term Investments figures came in at $25.8 million (Q1 2026), $23.7 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.